Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Sepracor, Inc. Patents
Assignee:
Sepracor, Inc.
Address:
Marlborough, MA
No. of patents:
319
Patents:


1 2 3 4 5 6 7










Patent Number Title Of Patent Date Issued
7902252 Inhibitors of D-amino acid oxidase March 8, 2011
The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating sympt
7893098 Pyrrole and pyrazole DAAO inhibitors February 22, 2011
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal functi
7884124 Fluoro-substituted inhibitors of D-amino acid oxidase February 8, 2011
This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and ne
7816375 Ligands for monoamine receptors and transporters, and methods of use thereof October 19, 2010
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The com
7812035 4-substituted piperidines, and methods of use thereof October 12, 2010
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The com
7790772 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine September 7, 2010
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is a
7776858 Methods of treatment of chronic pain using eszopiclone August 17, 2010
The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
7732641 Formoterol tartrate process and polymorph June 8, 2010
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
7723324 Imidazo[1,2-A]pyridine anxiolytics May 25, 2010
Imidazo[1,2-a]pyridines of the formulae I and II: ##STR00001## are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is: ##STR00002##
7718822 Carbamate Stereoisomer May 18, 2010
The compound of formula (I) ##STR00001## is a water-stable, long acting .beta..sub.2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.
7714023 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or cit May 11, 2010
Methods for prophylaxis of or treating or preventing migraine or migraine headaches, or other headache disorders include administering to a subject in need of treatment a therapeutically effective amount of citalopram, escitalopram, or a racemic or optically pure citalopram metabolite, o
7692019 Methods for the stereoselective synthesis of substituted piperidines April 6, 2010
One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will find use in the synthesis of
7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof March 2, 2010
One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, condition
7615572 Pyrrole and pyrazole DAAO inhibitors November 10, 2009
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal functi
7589237 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine September 15, 2009
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is a
7579370 Fused heterocycles August 25, 2009
This invention provides fused heterocycles having the formula: ##STR00001## in which R.sup.1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R.sup.2 is a member selected from the group cons
7566725 Imidazo[1,2-A] pyridine anxiolytics July 28, 2009
Imidazo[1,2-a]pyridines of the formulae I and II: ##STR00001## are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is: ##STR00002##
7517892 Ligands for monoamine receptors and transporters, and methods of use thereof April 14, 2009
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The com
7511141 Piperidine-piperazine ligands for neurotransmitter receptors March 31, 2009
One aspect of the present invention relates to piperidine-piperazine compounds. A second aspect of the present invention relates to the use of the piperidine-piperazine compounds as ligands for various mammalian cellular receptors or transporters or both, including dopamine, serotonin
7511073 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof March 31, 2009
One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, condition
7488747 Pyrrole and pyrazole DAAO inhibitors February 10, 2009
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal functi
7479572 Formoterol tartrate process and polymorph January 20, 2009
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
7468362 Carbonate and carbamate modified forms of glucocorticoids in combination with .beta..sub.2 adren December 23, 2008
Compositions containing .beta..sub.2 adrenergic agonists in combination with carbonates and carbonates of the formula ##STR00001## and in combination with related steroid carbonates and carbonates are disclosed. The compositions are useful for treating bronchospasm, for inducing bro
7465729 Methods of treatment of menopause and perimenopause using eszopiclone December 16, 2008
The invention relates to the use of eszopiclone for the treatment of symptoms accompanying perimenopause or menopause.
7456173 Compositions comprising zopiclone derivatives and methods of making and using the same November 25, 2008
The invention is directed to racemic and stereomerically pure compounds of Formula 3: ##STR00001## and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.
7446115 Peptidomimetic ligands for cellular receptors and ion channels November 4, 2008
One aspect of the present invention relates to novel peptidomometic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands--agonists or antagonists--for various cellular receptors, e.g., G-protein-coupled receptors and
7423179 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine September 9, 2008
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is
7390796 Fatty acid modified forms of glucocorticoids June 24, 2008
Compounds are disclosed of the formula ##STR00001## in which R.sup.3 is C.sub.8 to C.sub.24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by local or topic
7381724 Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compos June 3, 2008
Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-- dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
7368120 Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol May 6, 2008
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
7361666 Heterocyclic analgesic compounds and methods of use thereof April 22, 2008
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and i
7342132 Formoterol tartrate process and polymorph March 11, 2008
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
7294637 Method of treating addiction or dependence using a ligand for a monamine receptor or transporter November 13, 2007
One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a
7256310 Levalbuterol salt August 14, 2007
Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
7253156 Carbonate and carbamate modified forms of glucocorticoids in combination with B.sub.2 adrenergic August 7, 2007
Compositions containing .beta..sub.2 adrenergic agonists in combination with carbonates and carbamates of the formula ##STR00001## and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bro
7217823 4,4-Disubstituted piperidines, and methods of use thereof May 15, 2007
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present inventio
7214684 Methods for the treatment of allergic rhinitis May 8, 2007
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
7214683 Compositions of descarboethoxyloratadine May 8, 2007
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
7211582 Methods for treating urticaria using descarboethoxyloratadine May 1, 2007
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
7189715 Compositions comprising zopiclone derivatives and methods of making and using the same March 13, 2007
The invention is directed to racemic and stereomerically pure compounds of Formula 3: ##STR00001## and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.
7166725 Benzo[d]isoxazol-3-ol DAAO inhibitors January 23, 2007
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal funct
7148353 Imidazo[1,2-a] pyridine anxiolytics December 12, 2006
Imidazo[1,2-a]pyridines of the formulae I and II: ##STR00001## are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is: ##STR00002##
7145036 Formoterol tartrate polymorph December 5, 2006
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
7132551 Ligands for monoamine receptors and transporters, and methods of use thereof November 7, 2006
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The com
7129228 Heterocyclic analgesic compounds and methods of use thereof October 31, 2006
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and i
7125874 Optically active 5H-pyrrolo[3,4-b] pyrazine derivative, its preparation and pharmaceutical compo October 24, 2006
Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-- dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
7115664 Peptidomimetic ligands for cellular receptors and ion channels October 3, 2006
One aspect of the present invention relates to novel peptidomimetic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands--agonists or antagonists--for various cellular receptors, e.g., G-protein-coupled receptors and
7105699 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine September 12, 2006
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is a
7098224 Hydroxylansoprazole methods August 29, 2006
Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is
7087785 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine August 8, 2006
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is a
1 2 3 4 5 6 7

 
 
  Recently Added Patents
Interposer having molded low CTE dielectric
Cooler
Switching device and electronic apparatus using the same
Image processing device and information storage medium including motion vector information calculation
Flat panel display
Wall flow type exhaust gas purification filter
Baseball themed hand clap maraca
  Randomly Featured Patents
Panel-mounted, low voltage terminal
Dust resistant airfoil cooling
Method and apparatus for gravel packing a zone in a well
Helmet accessory
Process to prepare a premium formulated fried egg
Pressure measuring apparatus
High withstand voltage M I S field effect transistor and semiconductor integrated circuit
Ion-suppressed ring laser gyro frames
Circuit and method for component communication
Device and method to minimize data latency and maximize data throughput using multiple data valid signals